Philip A. Thompson

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

Enli Liu, David Marín, Pinaki P. Banerjee et al. · New England Journal of Medicine · 2020 · 2.1K citations · Full text

Life Sciences, Immunology, Oncology +17

Ibrutinib and Venetoclax for First-Line Treatment of CLL

Nitin Jain, Michael J. Keating, Philip A. Thompson et al. · New England Journal of Medicine · 2019 · 504 citations · Full text

Medicine, Hematology, Oncology +17

Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia

Philip A. Thompson, Constantine S. Tam, Susan O’Brien et al. · Blood · 2015 · 503 citations · Full text

Medicine, Immunology, Oncology +12

Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies

Romain Guièze, Vivian M. Liu, Daniel Rosebrock et al. · Cancer Cell · 2019 · 360 citations · Full text

Life Sciences, Cell Biology, Oncology +16

10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial

Courtney D. DiNardo, Abhishek Maiti, Caitlin R. Rausch et al. · The Lancet Haematology · 2020 · 331 citations · Full text

Medicine, Hematology, Oncology +16